No­var­tis says Kym­ri­ah reach­es pri­ma­ry end­point in new PhII, al­though num­bers still to come

The race to de­vel­op CAR-T ther­a­pies has died down since No­var­tis’ Kym­ri­ah and Gilead’s Yescar­ta first crossed the fin­ish line, though Tecar­tus al­so re­cent­ly re­ceived ap­proval. But the com­pa­nies con­tin­ue to ex­pand their drugs’ ap­pli­ca­tions, with No­var­tis prepar­ing to con­clude a new Phase II.

In­ter­im da­ta an­nounced by the Swiss phar­ma show that Kym­ri­ah met its pri­ma­ry end­point of com­plete re­sponse rate in treat­ing pa­tients with re­lapsed or re­frac­to­ry fol­lic­u­lar lym­phoma, the sec­ond-most com­mon form of non-Hodgkin lym­phoma. Based on pre­lim­i­nary tri­al find­ings, Kym­ri­ah had re­ceived RMAT des­ig­na­tion from the FDA in April for r/r fol­lic­u­lar lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER